This role provides pivotal medical leadership across the entire product lifecycle for AstraZeneca's injectable obesity therapies including SARA and GLP1/GCGR agonists.
Base: $283,386 to $425,080 annually; Bonus/Equity: Short-term incentive bonus and equity-based long-term incentive program available; Benefits: Qualified retirement program, paid vacation, holidays, leaves, and full health coverage
Must-have
Nice-to-have
Not specified